|
Malignant Head and Neck Neoplasm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, the combinations of CYP1A1 (AA) and CYP2D6 (CC) genotypes decreased risk of HNC (OR 0.20; P = 0.006).
|
24449363 |
2014 |
|
Primary malignant neoplasm
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The results indicated that there is a 3-fold increase in risk of developing this cancer in the presence of one copy of the variant CYP2D6 (HEM) allele and null GSTT1.
|
15588859 |
2005 |
|
Lewy Body Variant of Alzheimer Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease.
|
9633694 |
1998 |
|
CYP2D6 polymorphism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Taking this new information into account, we have reconsidered the potential influence of CYP2D6 polymorphism in lung cancer susceptibility by performing a comparative analysis of the overall mutational spectrum of CYP2D6 and of the rearrangements of CYP2D in 249 patients with lung cancer and in 265 control individuals matched on age, sex, hospital and residence area.
|
9511176 |
1998 |
|
Treatment-resistant schizophrenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A patient with treatment-resistant schizophrenia and cytochrome P4502D6 gene duplication.
|
11940091 |
2002 |
|
Head and Neck Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, the combinations of CYP1A1 (AA) and CYP2D6 (CC) genotypes decreased risk of HNC (OR 0.20; P = 0.006).
|
24449363 |
2014 |
|
Sporadic Parkinson disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Four polymorphic sites (C/T188, C/T2938, G/C4268, G/A1934) in the cytochrome P4502D6 (debrisoquine 4-hydroxylase) gene were investigated for their association with sporadic Parkinson's disease (PD).
|
10210913 |
1999 |
|
Mental Depression
|
0.210 |
Biomarker
|
disease |
BEFREE |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
|
30195732 |
2018 |
|
Mental Depression
|
0.210 |
Biomarker
|
disease |
RGD |
Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression.
|
20595028 |
2010 |
|
Parkinson Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians.
|
10210913 |
1999 |
|
Hepatitis C
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
We have refined the location of one possible tumour suppressor gene to the region between the microsatellite markers D22S299 and CYP2D.
|
10956388 |
2000 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q.
|
8631002 |
1996 |
|
Autoimmune Chronic Hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.
|
2466049 |
1989 |
|
Autoimmune Chronic Hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
|
Agnosia for Pain
|
0.020 |
Biomarker
|
disease |
BEFREE |
Inducing brain CYP2D with nicotine did not alter acute morphine analgesia (1.03-fold; p>0.8), or the rate of morphine tolerance (8.1%/day versus 7.6%; p>0.9).
|
28837793 |
2017 |
|
Autoimmune hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
|
Autoimmune hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.
|
2466049 |
1989 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
The gene encoding the phase I enzyme cytochrome P4502D6 (CYP2D6) has been previously investigated for its potential predictive role in the efficacy of breast cancer treatments such as tamoxifen, but its role in breast cancer susceptibility is unclear.
|
21527579 |
2011 |
|
Catalepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Selective inhibition and induction of brain, but not liver, CYP2D decreased and increased catalepsy after acute haloperidol, respectively.
|
28454738 |
2017 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
|
30195732 |
2018 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
The simulated diabetes in CYP2D poor metabolizers showed reduced metabolic ratios for M1 enantiomers.
|
30502451 |
2019 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
The simulated diabetes in CYP2D poor metabolizers showed reduced metabolic ratios for M1 enantiomers.
|
30502451 |
2019 |
|
Gilbert Disease (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Gilbert's syndrome, a genetic deficiency in bilirubin UDP-glucuronosyltransferase (UGT1A1), may dispose to increased toxicity of propafenone in poor metabolizers (PMs) of cytochrome P4502D6 because glucuronidation of propafenone is the major metabolic pathway for drug elimination in PMs.
|
10850406 |
2000 |
|
Caffeine related disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The five probe substrates were caffeine (2 mg/kg), bupropion (30 mg/kg), omeprazole (4 mg/kg), dextromethorphan (40 mg/kg), and midazolam (2 mg/kg) for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A, respectively.
|
29550976 |
2018 |